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Advances in the management of patients with acute coro-
nary syndromes (ACS) have evolved dramatically over the
past decade and, in many respects, represent a rapidly
moving target for the cardiologist or internist who seeks to
integrate these recent developments into contemporary
clinical practice (1,2). Traditionally, the approach to treat-
ing ACS patients has predominantly involved the rapid
initiation of intensive medical management, followed by
noninvasive risk stratification to identify those who need
urgent catheterization and possible revascularization versus
continued medical therapy alone (3–5).
Patients with unstable angina (UA) and non–ST-
segment elevation myocardial infarction (NSTEMI) com-
prise a growing subgroup of patients with ACS, producing
a major public health problem worldwide, especially in
Western countries, despite significant improvements and
refinements in management over the past 20 years. In the
U.S. alone, over 2.4 million people present with ACS each
year, with more than six million individuals undergoing
in-hospital vascular and cardiac surgery and related proce-
dures (6). Consequently, much attention has been directed
toward optimizing the diagnosis and management of such
patients, particularly in light of the continued evolution of
catheter-based interventions and newer pharmacologic
strategies that afford more complete platelet and thrombin
inhibition. When used together, these approaches appear to
have an important synergistic effect in reducing prognosti-
cally important ischemic events (7–12).
Various randomized, controlled clinical trials have estab-
lished the scientific foundation upon which evidence-based
treatment strategies have emerged and become increasingly
refined. Against this backdrop, the clinician is frequently
confronted with a panoply of choices that can create
uncertainty or confusion regarding “optimal management.”
The debate about the ideal approach to the management of
NSTE ACS (i.e., routine “early invasive strategy” versus an
“ischemia-guided” or “conservative” strategy) has been on-
going for over a decade (3–5,7–9). Recently, compelling
evidence from randomized clinical trials has demonstrated
that intermediate- and high-risk ACS patients derive sig-
nificant reductions in both morbidity and mortality with
mechanical or surgical intervention, especially when revas-
cularization is coupled with aggressive, multifaceted (anti-
platelet, antithrombin, anti-ischemic and antiatherogenic)
medical therapy (10–12).
When one considers the various pharmacologic options
available (low molecular-weight heparins [LMWHs], un-
fractionated heparin [UFH], glycoprotein (GP) IIb/IIIa
inhibitors, thienopyridines, plus the more “time-honored”
treatments of aspirin, intravenous (IV) nitroglycerin, beta-
blockers, statins and other dyslipidemic agents, and
angiotensin-converting enzyme [ACE] inhibitors), the
myriad possible drug combinations, and the important role
of establishing prompt coronary reperfusion with either
catheter-based intervention or surgical revascularization, it
is easy to understand how complex and difficult the
decision-making process has become for cardiologists,
emergency medicine physicians, intensivists, and hospital
pharmacists.
For these reasons, it seems especially timely and appro-
priate to undertake a comprehensive review of the latest
advances in the management of NSTE ACS, mindful of the
fact that even this noble effort to synthesize and integrate a
prodigious amount of scientific information and cardiovas-
cular therapeutics is destined to evolve still further as our
full-scale assault on optimizing clinical outcomes by harmo-
nizing the advances in mechanical and pharmacologic in-
terventions continues unabated.
In this unique supplement to the Journal of the American
College of Cardiology, we have assembled a distinguished
international faculty of 16 clinical scientists, trialists,
subject-matter experts, and opinion leaders. Their superla-
tive contributions have shaped and honed the many diag-
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nostic and therapeutic facets of this challenging and increas-
ingly common clinical syndrome.
Dr. Valentin Fuster provides an important and lucid
introduction to the Pathogenetic Concepts of Acute Coronary
Syndromes. In his report he describes the role of plaque
disruption as a major determinant of future ischemic events,
and the interdependent atherosclerotic and thrombotic pro-
cesses that are becoming increasingly integrated under the
term “atherothrombosis.” Inflammation, as a major deter-
minant of both plaque vulnerability and thrombogenicity
upon plaque disruption, and the pivotal role that the
endothelium plays in vascular homeostasis and hemostasis,
are both reviewed in considerable detail.
Dr. Prediman K. Shah then discusses the Mechanisms of
Plaque Vulnerability and Rupture. In this elegant contribu-
tion, Dr. Shah reviews the role of coronary thrombosis in
the genesis of acute ischemic syndromes leading to acute
MI, UA, and sudden cardiac death. He describes the
constituents of the so-called vulnerable plaque: thin fibrous
cap, upstream propagation of thrombus from the site of cap
rupture, and the roles of lipid and inflammation in mediat-
ing the development and progression of atherosclerotic
plaques. He also discusses the effects produced by reducing
lipids and inflammation in atherosclerotic plaques for de-
creasing the risk of plaque rupture and subsequent throm-
bosis.
Next, Dr. Carl J. Pepine discusses the exciting concept of
Pharmacologic Plaque Passivation for the Reduction of Recur-
rent Cardiac Events in Acute Coronary Syndromes. Passivation
of vulnerable plaque represents an essential therapeutic
strategy that can prevent or limit the magnitude of a new
rupture to reduce the recurrence or severity of events. The
author has explored the use of pharmacological agents
targeting plaque vulnerability and passivation, including
lipid-modifying agents (e.g., statins), antiplatelet agents
(acetylsalicylic acid, thienopyridines, GP IIb/IIIa inhibi-
tors), and antithrombotic agents (UFH and LMWH), and
has examined their potential role in reducing the occurrence
of acute coronary events in ACS patients.
Dr. E. Magnus Ohman then reviews the vital role of
Troponin: An Important Prognostic Marker and Risk Strati-
fication Tool in Non–ST-Segment Elevation Acute Coronary
Syndromes. In recent years, the development of highly
sensitive and cardiac-specific troponin assays has resulted in
a consensus change in the definition of MI, placing in-
creased emphasis on cardiac marker testing with troponins
as the new “gold standard.” Perhaps more importantly, Dr.
Ohman has described the establishment of the troponins as
superior markers of subsequent cardiac risk in ACS patients
and the role these markers play in identifying patients with
ACS who may derive particular benefit from potent anti-
thrombotic and antiplatelet therapy or early invasive treat-
ment strategies.
It has, however, become increasingly clear that biomark-
ers alone do not provide the only basis for delineating
subsets of ACS patients at high risk for developing recurrent
events. Dr. Paul Ridker reviews the increasingly important
role of C-Reactive Protein and Other Inflammatory Risk
Markers in Acute Coronary Syndromes. In his report, Dr.
Ridker highlights the fact that many ACS patients without
evidence of myocyte necrosis are at high risk for recurrent
ischemic events. Given the role of inflammatory processes in
determining plaque stability, recent work has focused on
whether plasma markers of inflammation may help improve
risk stratification. Of these markers, C-reactive protein
(CRP) has been the most widely studied. There is evidence
that CRP is a strong predictor of cardiovascular risk among
apparently healthy individuals, patients undergoing elective
revascularization procedures, and patients presenting with
ACS. Initial evidence suggests that the benefits of lifestyle
modification and drug therapy with aspirin or statins may be
greatest among those with elevated CRP levels.
Dr. Christopher Cannon then shifts to a discussion of
Small Molecule Glycoprotein IIb/IIIa Receptor Inhibitors as
Upstream Therapy in Acute Coronary Syndromes, focusing on
the results of the TACTICS TIMI-18 trial. Several large
trials have shown GP IIb/IIIa inhibition to be beneficial in
UA/NSTEMI either in patients treated predominantly with
medical management, early interventional management, or
both. These agents appear to be of greatest benefit in
patients at higher risk—for example, those with a positive
troponin at baseline, those with diabetes or ST-segment
depression, recurrent angina, prior aspirin use, or a Throm-
bolysis in Myocardial Infarction (TIMI) risk score 4.
These results provide evidence to physicians that early GP
IIb/IIIa inhibition in combination with a prompt invasive
approach should be utilized more widely in UA/NSTEMI
patients, particularly those at high risk.
To complete the discussion of the role of GP IIb/IIIa
agents in ACS patients, Dr. David Moliterno discusses the
data in support of using Glycoprotein IIb/IIIa Inhibition in
Early Intent-to-Stent Treatment of Acute Coronary Syn-
dromes: EPISTENT, ADMIRAL, CADILLAC, and TAR-
GET. The ACSs, with or without ST-segment elevation,
share a common pathophysiology of activated platelets and
thrombin generation stimulated by plaque erosion and
rupture. Both mechanical and pharmacologic treatment
strategies have evolved in an attempt to improve reperfusion
at the myocardial tissue level. When used with intracoronary
stents, potent platelet inhibition from IV GP IIb/IIIa
antagonists has reduced the rate of periprocedural MI and
late mortality. In particular, abciximab has well-established
clinical benefits in percutaneous revascularization trials, and
several recent landmark studies have evaluated the efficacy of
concomitant abciximab during mechanical reperfusion ther-
apy in the setting of ACS. These trials are reviewed and an
overall perspective is provided.
Dr. Marc Cohen provides an important commentary and
perspective on the emerging Role of Low-Molecular-Weight
Heparin in the Management of Acute Coronary Syndromes.
Several studies have consistently demonstrated that
LMWH compounds are effective and safe alternative anti-
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coagulants to UFH and improve clinical outcomes in ACS
patients. Of the several LMWH agents that have been
studied in large clinical trials, including enoxaparin, dalte-
parin, and nadroparin, not all have shown better efficacy
than UFH. Enoxaparin is the only LMWH compound to
have demonstrated sustained clinical and economic benefits
in comparison with UFH in the management of UA/
NSTEMI. Enoxaparin may also be a reliable and effective
antithrombotic treatment as adjunctive therapy in patients
undergoing percutaneous coronary intervention (PCI). The
most recent modifications to the American College of
Cardiologists/American Heart Association (ACC/AHA)
Management Guidelines for patients with NSTE ACS now
advocate enoxaparin as a Class I indication for antithrombin
therapy.
Dr. Sonia Anand provides an important overview of a
therapeutic approach utilizing Oral Anticoagulants in Pa-
tients With Coronary Artery Disease, a class of drugs not often
regarded by clinicians as efficacious for ACS patients.
In her report, Dr. Anand undertakes a systematic review
of the role of oral anticoagulants, with and without anti-
platelet therapy, in patients with established coronary artery
disease. The results revealed that high-intensity oral anti-
coagulation with an international normalized ratio (INR)
target of 2.8 significantly reduced cardiovascular compli-
cations but increased bleeding compared to controls. Low-
intensity oral anticoagulation (INR 2), in the presence of
aspirin, did not reduce cardiovascular complications, but
increased bleeding compared to aspirin alone. Moderate-
intensity oral anticoagulation (INR 2–3) was found to
reduce cardiovascular complications compared to controls.
The combination of aspirin plus moderate-intensity oral
anticoagulation proved to be more effective and just as safe
as aspirin alone. Moderate-intensity oral anticoagulation,
therefore, used together with aspirin, reduces recurrent
cardiovascular events and is relatively safe compared to
aspirin alone when used in patients with established coro-
nary artery disease.
Next, Dr. John Eikelboom highlights The Evolving Role
of Direct Thrombin Inhibitors in Acute Coronary Syndromes.
Thrombin plays a central role in the initiation and propa-
gation of intravascular thrombus, providing a strong ratio-
nale for using direct thrombin inhibitors in ACS patients.
Whereas the heparins block only circulating thrombin,
direct thrombin inhibitors block both circulating and clot-
bound thrombin. The Direct Thrombin Inhibitor Trialists’
Collaboration meta-analysis confirmed the superiority of
direct thrombin inhibitors, particularly hirudin and bivaliru-
din, over UFH for the prevention of death or MI during
treatment of ACS patients. These results were due to
primarily a reduction in MI (odds ratio, 0.80; 95% confi-
dence interval, 0.70 to 0.91) with little impact on death.
These and other preliminary data support the potential
benefit of bivalirudin over heparin for the prevention of
death or MI at 30 days, but further studies in ACS are
warranted.
Drs. Salim Yusuf and Shamir Mehta discuss the expand-
ing role of Short- and Long-Term Oral Antiplatelet Therapy
in Acute Coronary Syndromes and Percutaneous Coronary
Intervention. The investigators highlight the central role
played by platelets in both the acute and long-term mani-
festations of atherothrombosis, especially in ACS where
there is a steep early rise in cardiovascular events, followed
by a long-term incremental increase in events. The Anti-
platelet Trialists Collaboration found a 46% reduction in
vascular events with antiplatelet therapy (mostly aspirin),
but despite treatment with aspirin and proven therapies,
recurrent events remain high. The Clopidogrel in Unstable
angina to prevent Recurrent Events (CURE) trial demon-
strated the significant short- and long-term benefits (up to
one year) of aspirin plus clopidogrel in reducing major
cardiovascular events (cardiovascular death, MI, and stroke
reduced by 20%, p  0.00009) in a broad range of ACS
patients. The benefits emerged very rapidly (within 2 h)
after a 300 mg loading dose, and they were likewise
observed in the large number of patients undergoing PCI in
CURE. Here, the benefit was observed regardless of
whether intervention was performed early or late. Because of
the broad-based benefits associated with clopidogrel in all
subgroups of ACS patients, the revised ACC/AHA Treat-
ment Guidelines have been updated in 2002 to include
clopidogrel as a Class I indication in all ACS patients.
Drs. Elliott Antman and Marc Sabatine review the utility
and clinical application of The Thrombolysis In Myocardial
Infarction Risk Score in Unstable Angina/Non–ST-Segment
Elevation Myocardial Infarction. Certainly, risk stratification
in ACS is important in quantifying an estimate of a patient’s
prognosis and as a guide to optimizing clinical choices. The
TIMI risk score for NSTE ACS represents an integrated
approach using baseline variables that are part of the routine
medical evaluation to identify patients at high risk for death
and other major cardiac ischemic events. Employing mul-
tivariable logistic regression of seven independent predictor
variables, a weighted risk score can be constructed as the
simple arithmetic sum of the number of predictors. The rate
of death, MI, or urgent revascularization significantly in-
creased as the TIMI risk score increased, ranging from5%
for patients with a risk score of 0 or 1 to 40% for patients
with a risk score of 6 or 7. Thus, the TIMI risk score
provides a clinically meaningful tool to define a gradient of
benefit for specific treatments such as LMWH, GP IIb/IIIa
inhibitors, and an early invasive strategy.
Which approach—an interventional, anatomically driven
one or a functional, biologically driven one—is preferable
for managing patients with NSTE ACS? Dr. Raymond
McKay and Dr. Steven Nissen address this ongoing con-
troversy in a lucid “point-counterpoint” discussion of these
differing management strategies. In his report, “Ischemia-
Guided” Versus “Early Invasive” Strategies in the Management
of Acute Coronary Syndrome/Non–ST-Segment Elevation
Myocardial Infarction: The Interventionalist’s Perspective, Dr.
McKay summarizes the key findings of more recent studies.
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Figure 1. Strategies for mechanical and pharmacologic intervention in acute coronary syndrome (ACS) patients. ACE  angiotensin-converting enzyme; ASA  acetylsalicylic acid; CABG  coronary artery
bypass graft; CAD coronary artery disease; CCU Cardiac Care Unit; CHF congestive heart failure; ECG electrocardiogram; GP glycoprotein; inflam inflammatory; IV intravenous; LBBB
left bundle branch block; LMWH  low molecular-weight heparin; MI  myocardial infarction; MPI  myocardial perfusion imaging; NTC  nitroglycerin; PCI  percutaneous coronary intervention;
TIMI  Thrombolysis In Myocardial Infarction; UFH  unfractionated heparin.
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Improved clinical outcomes have been demonstrated with
the use of an “early invasive” approach, employing routine
coronary angiography early in the patient’s hospital course,
followed by PCI or bypass surgery. The emerging role for
the combined use of GP IIb/IIIa inhibitors and intracoro-
nary stenting, which may reduce the potential early hazard
of an invasive approach by specifically decreasing the inci-
dence of death and nonfatal MI associated with PCI, is also
discussed. In this overview, Dr. McKay highlights the
importance of PCI to treat “culprit” lesions as part of a
broader treatment strategy employing a combination of
aggressive medical therapy to treat the widespread coronary
atherosclerosis commonly seen in ACS patients.
In his related report, Dr. Nissen endorses the opposing
view that Pathobiology, Not Angiography, Should Guide Man-
agement in Acute Coronary Syndrome/Non–ST-Segment Ele-
vation Myocardial Infarction: The Non-Interventionist’s Per-
spective. In this provocative essay, Dr. Nissen concedes that,
while an “early invasive” strategy (angiography and PCI) is
the convention in ACS/NSTEMI management in the
United States, a conservative pharmacologic approach is
common in other countries. Identification of hemodynam-
ically significant stenoses may be confounded by coronary
“remodeling” and most plaques, particularly those respon-
sible for acute events, are “extraluminal.” Assessment of the
luminal diameter of a lesion, which requires comparison
with a “normal” reference segment, may be impossible
because of the diffuse nature of the disease, and PCI
following plaque rupture may itself cause embolization and
“no-reflow” phenomena leading to severe complications.
The inability of angiography to depict the true extent of
atherosclerosis is supported by necropsy and transplant
donor studies. Statins, beta-blockers, and ACE inhibitors
decrease the incidence of death and MI by stabilizing
atherosclerotic plaques throughout the coronary bed, reduc-
ing inflammation, collagen degradation, tissue factor ex-
pression, and vasomotor tone.
Dr. William Boden reviews the continuing controversy
regarding the “Routine Invasive” versus “Selective Invasive”
Approaches to Non–ST-Segment Elevation Acute Coronary
Syndromes Management in the Post-Stent/Platelet Inhibition
Era. Dr. Boden poses an important question: Does a
“routine invasive” or “selective invasive” strategy constitute
the best management approach for patients who present
with NSTE ACS? Two trials, the second Fragmin and fast
Revascularization during InStability in Coronary artery
disease (FRISC-II) and the Treat angina with Aggrastat
and determine Cost of Therapy with an Invasive or Con-
servative Strategy–Thrombolysis in Myocardial Infarction
(TACTICS TIMI-18), have demonstrated significant re-
ductions in death, recurrent MI, or hospitalization for
biomarker-positive ACS during 6- to 12-month follow-up
when myocardial revascularization was undertaken two to
six days after symptom onset. Importantly, while FRISC-II
and TACTICS TIMI-18 indicated benefit for patients with
ST-depression and/or elevated serum levels of biomarkers
(troponin or creatine kinase) who received the early inter-
ventional approach, patients who did not have these char-
acteristics benefited equally from an invasive or conservative
approach.
More recent results from the third Randomized Inter-
vention Trial of unstable Angina (RITA-3) also found a
significant reduction in the combined risk of death, nonfatal
MI, or refractory angina with early intervention, mainly
attributable to a decrease in angina. Subjects enrolled in
RITA-3 tended to be at lower risk (younger, more female
subjects, fewer or no diseased vessels) than those in
FRISC-II or TACTICS TIMI-18. The benefits of early
intervention in RITA-3 were strongly gender-linked, with
significant reductions in the composite of death and MI
limited to men. Trends to an increased hazard with early
intervention were revealed in female subjects. Thus, man-
agement that incorporates both invasive and conservative
strategies—and one that, ultimately, tailors therapy to the
level of risk—is both appropriate and evidence-based.
Finally, in the concluding report of these 16 invited
papers, Dr. Eric Topol offers a practical synthesis in A Guide
to Therapeutic Decision-Making in Patients With Non–ST-
Segment Elevation Acute Coronary Syndromes. In this sum-
mary, Dr. Topol highlights recent clinical trial evidence
supporting both an inflammatory and atherothrombotic
etiology in acute ischemic heart disease. For example, when
a segment of coronary artery becomes inflamed, important
cytokines, such as tissue factor, are released, facilitating
thrombosis; as a consequence, serum inflammatory markers
are elevated in most ACS patients at presentation. Impor-
tantly, mortality risk has been shown to be associated with
increased levels of high-sensitivity CRP, interleukin-6, and
serum vascular cell adhesion molecule while platelets, which
are rich in inflammatory mediators (CD40 and its ligand,
thrombospondin, and phospholipase A2), also supply im-
portant triggers for the inflammatory cascade.
Regardless of whether an “invasive” or “conservative”
strategy is employed, clinicians must now weigh the role of
new agents from three distinct drug classes—GP IIb/IIIa
inhibitors, LMWHs, and clopidogrel, which have recently
flooded the therapeutic armamentarium together with more
traditional secondary prevention strategies (aspirin, beta-
blockers, nitrates, and statins). To this end, a schema depicting
the strategies of mechanical and pharmacologic intervention is
provided to guide therapeutic decision making in the compre-
hensive management of ACS patients (Fig. 1).
In summary, we believe that this substantive Journal
supplement will provide clinicians with a relevant and timely
review of a common syndrome that beckons us to pause and
reflect upon achievements gained and challenges that will
confront us in the years to come. We hope you will find this
collection of 16 papers by a cadre of world-renowned
subject-matter experts and opinion leaders a valuable re-
source to facilitate and optimize both the management and,
more importantly, clinical outcomes of all patients with
NSTE ACS.
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